Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPRESS: Meropenem vs Piperacillin/Tazobactam in Sepsis
NCT06184659Phase 4Recruiting
- Sponsor
- Scandinavian Critical Care Trials Group
- Start
- Jun 2025
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of meropenem in sepsis, sponsored by Scandinavian Critical Care Trials Group. Started Jun 2025; status: recruiting.
02
Drugs
meropenem
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT06184659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06184659.